Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Acadia Pharmaceuticals (ACAD)

Acadia Pharmaceuticals R&D Head Thompson Retires, Becomes Consultant Through Dec 31

Neutral Impact 3 of 5 leadership

Acadia Pharmaceuticals said Elizabeth H.Z. Thompson, its Executive Vice President and Head of Research and Development, is retiring from her employee role effective October 23, 2026. She will remain with the company as a consultant, providing limited services through December 31, 2026, and the company is searching for a replacement.

Key points

  • Dr. Elizabeth H.Z. Thompson informed the company of her planned retirement on April 27, 2026, for personal reasons
  • Effective October 23, 2026, she no longer serves as an employee or as Head of Research and Development
  • She will be retained as a consultant and intends to provide limited consulting services through December 31, 2026
  • The company is in the process of identifying a replacement Head of Research and Development

The filing

CompanyAcadia Pharmaceuticals (ACAD)
Form8-K, current report
Filed with the SECOct 23, 2026, 4:51 PM ET
Accession number0001193125-26-430596

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 7, 2026, 11:17 PM ET, from the text of the filing and its press-release exhibits only.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.